目次

Table of Content

1. RESEARCH METHODOLOGY

2. Introduction to Selective Estrogen Receptor Degraders (SERDs)
2.1 Overview and Evolution of SERDs
2.2 Selective Estrogen Receptor Degraders - Mechanism of Action
2.3 Selective Estrogen Receptor Degraders in Combination Therapies

3. Application Of Selective Estrogen Receptor Degraders By Indication
3.1 Breast Cancer
3.2 Other Cancers
3.3 Other Applications

4. Selective Estrogen Receptor Degrader Market Analysis
4.1 Commercially Approved Selective Estrogen Receptor Degraders
4.2 Current Market Scenario
4.3 Future Commercialization Opportunity

5. Selective Estrogen Receptor Degrader Clinical Trials Overview
5.1 By Company
5.2 By Country
5.3 By Indication
5.4 By Patient Segment
5.5 By Phase

6. Selective Estrogen Receptor Degrader (SERD) Clinical Trials Insight
6.1 Phase I
6.2 Phase-I/II
6.3 Phase-II
6.4 Phase-III

7. Marketed Selective Estrogen Receptor Degrader (SERD) Insight

8. Faslodex - 1st Commercially Available Selective Estrogen Receptor Degrader
8.1 Approval and Patent Overview
8.2 Pricing and Dosage Analysis
8.3 Sales Analysis
8.4 Faslodex - Reimbursement Scenario

9. Generic Fulvestrant - Availability and Price Analysis

10. Orserdu - 2nd Commercially Available Selective Estrogen Receptor Degrader
10.1 Approval and Patent Overview
10.2 Pricing and Dosage Analysis
10.3 Orserdu - Reimbursement Scenario

11. Competitive Landscape
11.1 AstraZeneca
11.2 Eli Lilly
11.3 EnhancedBio
11.4 Olema Oncology
11.5 Radius Therapeutics
11.6 Roche

List of Figures
Figure 2-1: Evolution of Selective Estrogen Receptor Degraders
Figure 2-2: Role of Estrogen Receptor in Tumor Development
Figure 2-3: Mechanism of Selective Estrogen Receptor Degraders
Figure 2-4: Mechanism of SERDs in Combination with other Cancer Therapeutics
Figure 2-5: CDK 4/6 Inhibitors Used in Combination with Selective Estrogen Receptor Degraders
Figure 2-6: PI3K Inhibitors Used in Combination with Selective Estrogen Receptor Degraders
Figure 2-7: Aromatase Inhibitors Used in Combination with Selective Estrogen Receptor Degraders
Figure 2-8: mTOR Inhibitors Used in Combination with Selective Estrogen Receptor Degraders
Figure 3-1: Breast Cancer - Estimated Incidence and Mortality (Millions), 2045
Figure 3-2: Selective Estrogen Receptor Degraders in Development
Figure 3-3: VERITAC-2 Phase 3 (NCT05654623) Trial - Study Initiation and Completion Year
Figure 3-4: VERITAC-3 Phase 3 (NCT05909397) Trial - Study Initiation and Completion Year
Figure 3-5: EvoPAR-BR01 Phase 3 (NCT06380751) Trial - Study Initiation and Completion Year
Figure 3-6: CAMBRIA-1 Phase 3 (NCT05909397) Trial - Study Initiation and Completion Year
Figure 3-7: CAMBRIA-2 Phase 3 (NCT05952557) Trial - Study Initiation and Completion Year
Figure 3-8: SERENA-4 Phase 3 (NCT04711252) Trial - Study Initiation and Completion Year
Figure 3-9: SERENA-6 Phase 3 (NCT04964934) Trial - Study Initiation and Completion Year
Figure 3-10: OPERA-01/OP-1250-301 Phase 3 (NCT06016738) Trial - Study Initiation and Completion Years
Figure 3-11: OP-1250-001 Phase 1/2 (NCT04505826) Trial - Study Initiation and Completion Years
Figure 3-12: OP-1250-003 Phase 1 (NCT04964934) Trial - Study Initiation and Completion Year
Figure 3-13: EMBER-3 Phase 3 (NCT04975308) Trial - Study Initiation and Completion Year
Figure 3-14: EMBER-4 Phase 3 (NCT05514054) Trial - Study Initiation and Expected Completion Year
Figure 3-15: persevERA Phase 3 (NCT04546009) Trial - Study Initiation and Expected Completion Year
Figure 3-16: lidERA Phase 3 (NCT04961996) Trial - Study Initiation and Expected Completion Year
Figure 3-17: heredERA Phase 3 (NCT05296798) Trial - Study Initiation and Expected Completion Year
Figure 3-18: evERA Phase 3 (NCT05306340) Trial - Study Initiation and Expected Completion Year
Figure 3-19: pionERA Phase 3 (NCT06065748) Trial - Study Initiation and Expected Completion Year
Figure 3-20: 2017-0405 Phase 2 (NCT03531645) Trial - Study Initiation and Expected Completion Year
Figure 3-21: 18-107 Phase 2 (NCT03643510) Trial - Study Initiation and Expected Completion Year
Figure 3-22: CASE2820 Phase 2 (NCT05113368) Trial - Study Initiation and Expected Completion Year
Figure 4-1: Fulvestrant and Elacestrant - Mechanism of Action
Figure 4-2: Selective Estrogen Receptor Degraders Market - Future Opportunities
Figure 5-1: SERD - Clinical Trials by Company (Number of Drugs), 2025 Till 2030
Figure 5-2: SERD - Clinical Trials by Country (Number of Drugs), 2025 Till 2030
Figure 5-3: SERD - Clinical Trials by Indication (Number of Drugs), 2025 Till 2030
Figure 5-4: SERD - Clinical Trials by Patient Segment (Number of Drugs), 2025 Till 2030
Figure 5-5: SERD - Clinical Trials by Phase (Number of Drugs), 2025 Till 2030
Figure 8-1: Faslodex - FDA Approval Years by Breast Cancer Type
Figure 8-2: Faslodex - FDA Approval Year and First Generic Approval Year
Figure 8-3: Faslodex - Price per Unit and Supply of Intramuscular Injection (US$), June’2024
Figure 8-4: Faslodex - Recommended and Reduced Dose (mg)
Figure 8-5: Faslodex - Number of Doses by Treatment Phase
Figure 8-6: Faslodex - Cost For First and Subsequent Treatment Cycles (US$)
Figure 8-7: Global - Faslodex Annual Sales (US$ Million), 2019-2023
Figure 8-8: US - Faslodex Annual Sales (US$ Million), 2019-2023
Figure 8-9: EU - Faslodex Annual Sales (US$ Million), 2019-2023
Figure 8-10: ROW - Faslodex Annual Sales (US$ Million), 2019-2023
Figure 8-11: Global - Faslodex Quarterly Sales (US$ Million), 2023
Figure 8-12: Global - Faslodex Annual Sales by Region (US$ Million), 2023
Figure 8-13: Global - Faslodex Annual Sales by Region (%), 2023
Figure 8-14: US - Faslodex Quarterly Sales (US$ Million), 2023
Figure 8-15: EU - Faslodex Quarterly Sales (US$ Million), 2023
Figure 8-16: ROW - Faslodex Quarterly Sales (US$ Million), 2023
Figure 9-1: Fulviglen - Price per Unit and Supply of 3 Intramuscular Injections (US$), July’2025
Figure 9-2: Fulviglen - Price per Unit and Supply of 6 Intramuscular Injections (US$), July’2025
Figure 9-3: Fulviglen - Price per Unit and Supply of 9 Intramuscular Injections (US$), July’2025
Figure 9-4: Fulvenat - Price per Unit and Supply of 120 mg Intramuscular Injection (US$), July’2025
Figure 9-5: Fulvenat - Price per Unit and Supply of 250 mg Intramuscular Injection (US$), July’2025
Figure 9-6: Fulvetraz - Price per Unit and Supply of 50 mg Intramuscular Injection (US$), July’2025
Figure 9-7: Fulvetraz - Price per Unit and Supply of 250 mg Intramuscular Injection (US$), July’2025
Figure 9-8: Fuvestrol - Price per Unit and Supply of 250 mg Intramuscular Injection (US$), July’2025
Figure 9-9: Strantas - Price per Unit and Supply of 250 mg Intramuscular Injection (US$), July’2025
Figure 9-10: Celvestrant - Price per Unit and Supply of 250 mg Intramuscular Injection (US$), July’2025
Figure 9-11: Faslomax - Price per Unit and Supply of 250 mg Intramuscular Injection (US$), July’2025
Figure 9-12: Fasnorm - Price per Unit and Supply of 250 mg Intramuscular Injection (US$), July’2025
Figure 9-13: India - Price per Unit and Supply of Fulveryze Intramuscular Injections (INR/US$), July’2025
Figure 9-14: India - Price per Unit and Supply of Vestrant Intramuscular Injections (INR/US$), July’2025
Figure 9-15: India - Price per Unit and Supply of Fulvether Intramuscular Injections (INR/US$), July’2025
Figure 9-16: India - Price per Unit and Supply of Fulveser Intramuscular Injections (INR/US$), July’2025
Figure 9-17: India - Price per Unit and Supply of Fulzos Intramuscular Injection (INR/US$), July’2025
Figure 9-18: India - Price per Unit and Supply of Fistent Intramuscular Injection (INR/US$), July’2025
Figure 9-19: India - Price per Unit and Supply of Fulpost Intramuscular Injection (INR/US$), July’2025
Figure 9-20: India - Price per Unit and Supply of Fulvested Intramuscular Injection (INR/US$), July’2025
Figure 9-21: India - Price per Unit and Supply of Fulvaa Intramuscular Injection (INR/US$), July’2025
Figure 9-22: India - Price per Unit and Supply of Fulbreca Intramuscular Injection (INR/US$), July’2025
Figure 9-23: India - Price per Unit and Supply of Fulvekast Intramuscular Injection (INR/US$), July’2025
Figure 9-24: Europe - Price for Supply of Teva Fulvestrant Intramuscular Injection (GBP/US$), July’2025
Figure 9-25: Europe - Price for Supply of Zentiva Fulvestrant Intramuscular Injection (GBP/US$), July’2025
Figure 9-26: Europe - Price for Supply of Sandoz Fulvestrant Intramuscular Injection (GBP/US$), July’2025
Figure 9-27: Europe - Price for Supply of AAH Fulvestrant Intramuscular Injection (GBP/US$), July’2025
Figure 9-28: Europe - Price for Supply of Thornton and Ross Fulvestrant Intramuscular Injection (GBP/US$), July’2025
Figure 9-29: Europe - Price for Supply of Dr. Reddy’s Fulvestrant Intramuscular Injection (GBP/US$), July’2025
Figure 9-30: Europe - Price for Supply of Kent Fulvestrant Intramuscular Injection (GBP/US$), July’2025
Figure 9-31: Europe - Price for Supply of Amneal Pharmaceuticals Fulvestrant Intramuscular Injection (GBP/US$), July’2025
Figure 10-1: Orserdu - US Patent Grant and Expiration years
Figure 10-2: Orserdu - Price per Unit and Supply of Oral Tablets (US$), July’2025
Figure 10-3: EU - Price per Unit and Supply of (US$), July’2025

List of Tables
Table 3-1: Breast Cancer - Selective Estrogen Receptor Degraders In Clinical Trials
Table 4-1: Globally Approved Branded SERDs
Table 10-1: Orserdu - Dose Reduction Levels for Adverse Reactions
Table 10-2: Orserdu - Dosage Modification Guidelines for Adverse Reaction